TY - BOOK ID - 218214 TI - Human antibody therapeutics for viral disease PY - 2008 SN - 1281134252 9786611134259 3540721460 3540721444 3642091318 PB - Berlin ; New York : Springer Verlag, DB - UniCat KW - Immunoglobulins. KW - Immunoglobulins KW - Virus diseases KW - Therapeutic use. KW - Treatment. KW - Chemotherapy. KW - Antiviral agents KW - Viral diseases KW - Viral infections KW - Virus infections KW - Communicable diseases KW - Medical virology KW - Pathogenic viruses KW - Antibodies KW - Immune globulins KW - Immune serum globulin KW - Blood proteins KW - Globulins KW - Plasma cells KW - Antibody diversity KW - Antigens KW - Bacterial immunoglobulin-binding proteins KW - Medical virology. KW - Virology. KW - Medical microbiology KW - Virology KW - Microbiology UR - https://www.unicat.be/uniCat?func=search&query=sysid:218214 AB - The articles in this volume have been selected to demonstrate the progress in the development of human antibody therapeutics for viral disease. Keck et al. review the nature of the immune response to the Hepatitis C virus (HCV) and the details of viral neutralization by antibodies, providing a conceptual model for the clinical use of HCV-specific antibodies. Huber et al. summarize the initial clinical experiences with antibody therapeutics for Human Immunodeficiency Virus that can be targeted to either the HIV virion or to host cell proteins. A discussion of the breadth immune strategies that is required to control human rabies is provided by Nagarajan et al., with a particular focus on India and other countries in which rabies is endemic. The development of pavilizumab for RSV prophylaxis is reviewed in Wu et al., in addition to results of antibody optimization studies that provide surprising insights and have broad general implications for anti-viral antibody engineering. Melhop and Diamond explicate the biology of West Nile Virus as a general model for flaviviruses, while using their cloned antibodies as a springboard to consider the mechanisms of WNV neutralization. The volume concludes with a description of methods to clone human antibodies in their native configurations, which access a class of antibodies that differ from those obtained by recombinant DNA or transgenic mouse methods. The articles in this volume are definitive and comprehensive reviews written by experts who have sought to define the principles of viral neutralization by human antibodies. They explore and anticipate the obstacles and opportunities that will be encountered as the power of human antibodies is harnessed to address the vast, un-met need for effective anti-viral therapeutics. ER -